Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07976016 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| PF-07976016 Dose 1 | EXPERIMENTAL | - |
| PF-07976016 Dose 2 | EXPERIMENTAL | - |
| PF-07976016 Dose 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Arm 1 | EXPERIMENTAL | Participants will receive doses of PF-07976016 with and without radiolabel. |
| Part A Cohort 1 | EXPERIMENTAL | Single dose administration of PF-07976016 and placebo. Participants will receive up to 4 dose levels of PF-07976016 or matching placebo. |
| Part A Cohort 2 | EXPERIMENTAL | Single dose administration of PF-07976016 and placebo. Participants will receive up to 4 dose levels of PF-07976016 or matching placebo. |
| Part A Optional Cohort 3 | EXPERIMENTAL | Single dose administration of PF-07976016 and placebo. Participants will receive up to 2 dose levels of PF-07976016 or matching placebo. |
| Part A Optional Cohort 4 | EXPERIMENTAL | Single dose administration of PF-07976016 and placebo. Participants will receive up to 4 dose levels of PF-07976016 or matching placebo. |
| Part B Cohort 5 | EXPERIMENTAL | Multiple dose administration of PF-07976016 or matching placebo. |
| Part B Cohort 6 | EXPERIMENTAL | Multiple dose administration of PF-07976016 or matching placebo. |
| Part B Cohort 7 | EXPERIMENTAL | Multiple dose administration of PF-07976016 or matching placebo. |
| Part B Cohort 8 | EXPERIMENTAL | Multiple dose administration of PF-07976016 or matching placebo. |
| Part B Cohort 9 | EXPERIMENTAL | Multiple dose administration of PF-07976016 or matching placebo. |
| Part B Optional Cohort 10 | EXPERIMENTAL | Multiple dose administration of PF-07976016 or matching placebo. |
| Part C Optional Cohort 11 | EXPERIMENTAL | Single dose midazolam administered alone or in combination with multiple doses of PF-07976016. |
| Part C Optional Cohort 12 | EXPERIMENTAL | Single dose midazolam administered alone or in combination with multiple doses of PF-07976016. |
| Part D Optional Cohort 13 | EXPERIMENTAL | Multiple dose administration of PF-07976016 or matching placebo. |
| Name | Type | Description |
|---|---|---|
| PF-07976016 | DRUG | Taken once daily |
| Placebo | DRUG | Taken once daily |
| [14C] PF-07976016 | DRUG | \[14C\] PF-07976016 liquid (oral) formulation |
| Midazolam | DRUG | Midazolam oral solution |
Key Inclusion Criteria: * Male or non-pregnant, non-breastfeeding female, 18 to 74 years of age at Visit 1 * Body Mass Index ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as \<5 kg change in the 12 weeks before Visit 1 * Eligible and willing to receive required background medicine * Will...
Top 20 of 32 competitors
PF-07976016 is an investigational small molecule being studied for the treatment of obesity and for use in healthy adults and healthy male volunteers. It is being developed by Pfizer, Inc. and has completed clinical trials in these populations.
PF-07976016 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in clinical development.
PF-07976016 is in clinical development. It has completed a Phase 1 study in healthy adults, a Phase 1 study in healthy male volunteers, and a Phase 2 study in adults with obesity. All three trials are completed.
PF-07976016 has been studied in three completed clinical trials. NCT06106009 was a Phase 1 trial in healthy adults in the United States. NCT06717425 was a Phase 2 trial in adults with obesity in the United States, Canada, and Poland. NCT07015918 was a Phase 1 trial in healthy male volunteers in the Netherlands.
PF-07976016 is an investigational drug and is not FDA approved. It is still in clinical development, with completed Phase 1 and Phase 2 trials. The drug is being studied for obesity and in healthy volunteers.
PF-07976016 is a small molecule being developed by Pfizer, Inc. Its molecular target has not been disclosed in the available clinical trial information. The drug is being studied for its effects in obesity and in healthy volunteers.